Emerging biosimilars for retinal diseases

Abstract

ABSTRACT Introduction Biosimilars for retinal diseases have been a topic of discussion recently due to the approval of two biosimilar ranibizumab by the US FDA and EMA. It is important to understand this emerging field in retina with many other biosimilar anti-VEGF molecules in the final stage of their trials. Hopefully, they will be available for clinical use very soon. Areas covered Articles update about the approved biosimilar ranibizumab for retinal diseases and list out ranibizumab and aflibercept biosimilars in the pipeline. Expert opinion Approval of biosimilar anti-VEGFs might be able to drive a geographically variable change in the usage of retinal pharmacotherapy based on the local policies of the health system.